Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study will perform a clinical study evaluating the safety and tolerability of nintedanib
when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic
pancreatic cancer. It will utilize advanced imaging correlates including dynamic contrast
enhanced Magnetic Resonance Imaging (DCE-MRI) which correlates with tumor grade and
microvessel density.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Boehringer Ingelheim South Plains Oncology Consortium The University of Texas Health Science Center at San Antonio